- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Immunologist Takes Scalpel to Merck R&D
1 October 2013 3:00 pm
Immunologist Roger Perlmutter is shaking things up again at Merck. After eliminating a corps of managers in June, the newly anointed Merck R&D chief is now following through on the “major surgery” that he promised in an interview in The Wall Street Journal last month. The drug giant will cut 8500 more jobs as part of its ongoing overhaul. The layoffs, amounting to roughly 20% of the workforce, are intended to cut operating expenses by $2.5 billion by the end of 2015, the company announced today in a press release.
Merck CEO Kenneth Frazier explained today in The Wall Street Journal that the firm aims to rebound from recent failures and devote more resources to the company’s most promising efforts, including cancer immunotherapy and diabetes research.